When was MeCo Diagnostics founded?

MeCo Diagnostics was founded in 2022 and raised its 1st funding round 1 year after it was founded.

Where is MeCo Diagnostics located?

MeCo Diagnostics is headquartered in San Diego, United States.

Who is the current CEO of MeCo Diagnostics?

Adam Watson of MeCo Diagnostics. They have also founded 1 company.

How many employees does MeCo Diagnostics have?

As of Aug 31, 2026, the latest employee count at MeCo Diagnostics is 8.

Is MeCo Diagnostics a funded company?

MeCo Diagnostics is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Jun 07, 2023.

When was the latest funding round of MeCo Diagnostics?

MeCo Diagnostics' latest funding was a $***** Seed round on Jun 07, 2023, with participation from 1 investor.

Where does MeCo Diagnostics rank among its competitors?

MeCo Diagnostics ranks 42nd amongst 85 active competitors, of which 37 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Mammogen, which secured $30M in Jun, 2026.

Who are the top competitors of MeCo Diagnostics?

MeCo Diagnostics' top competitors include ScreenPoint, PreludeDx and Syantra Health. Among them, Mammogen secured the most recent funding round in June, 2026.

MeCo Diagnostics - 2026 Company Profile, Team, Funding & Competitors

MeCo Diagnostics is a seed company based in San Diego (United States), founded in 2022 by Adam Watson. It operates as a Developer of predictive biomarker tests for breast cancer care. MeCo Diagnostics has raised an undisclosed amount in funding from EvoNexus. The company has 85 active competitors, including 37 funded and 9 that have exited. Its top competitors include companies like ScreenPoint, PreludeDx and Syantra Health.

Company Details

Developer of predictive biomarker tests for breast cancer care. The company's mission is to predict and prevent cancer metastasis by leveraging low-toxicity, repurposed drugs for minimally disruptive therapy without displacing standard-of-care treatments.

Key Metrics

Founded Year

2022

Location

San Diego, United States

Stage

Seed

Latest Funding Round

Seed, Jun 07, 2023, $*****

Investors

EvoNexus & 2 more

Ranked

42^nd among 85 active competitors

Employee Count

8 as on Aug 31, 2026

Similar Companies

ScreenPoint & 120 more

View MeCo Diagnostics' full profile

MeCo Diagnostics has raised funding over 1 round. Its latest funding round was a Seed round on Jun 07, 2023 for $*****. 1 investor participated in its latest round. MeCo Diagnostics has 3 institutional investors.

Here is the list of recent funding rounds of MeCo Diagnostics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 07, 2023	5782713	Seed	4851900	5642131	8658664	4230417

Access funding benchmarks and valuations. Sign up today!

View details of MeCo Diagnostics's funding rounds and investors

The founders of MeCo Diagnostics is Adam Watson. Adam Watson is the CEO of MeCo Diagnostics.

Here are the details of MeCo Diagnostics' key team members:

Adam Watson: Co-Founder & CEO of MeCo Diagnostics.

View details of MeCo Diagnostics's Founder profiles and Board Members

MeCo Diagnostics' employee count trend

MeCo Diagnostics has 8 employees as of Aug 26. Here is MeCo Diagnostics's employee count trend over the years:

Employee count trend for MeCo Diagnostics

Uncover MeCo Diagnostics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MeCo Diagnostics include ScreenPoint, PreludeDx and Syantra Health. Here is the list of Top 10 competitors of MeCo Diagnostics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	ScreenPoint 2014, Nijmegen (Netherlands), Series C	Developer of artificial intelligence software for analyzing breast imaging mammograms	$47M	Insight Partners, Siemens & 3 others	64/100
2nd	PreludeDx 2009, Laguna Hills (United States), Series B	Provider of risk assessment test for early stage breast cancer	$51.7M	Evidity Health Capital, GenesisCare & 2 others	57/100
3rd	Syantra Health 2013, Calgary (Canada), Series A	Developer of a blood test device to detect breast cancer	$10.4M	Plug and Play Tech Center, The51 & 5 others	54/100
4th	Isotropic Imaging 2016, Las Vegas (United States), Public	Innovating breast cancer imaging with dedicated 3D breast CT technology	-	-	48/100
5th	Mammogen 2020, Aliso Viejo (United States), Series A	Developer of a diagnostic test to detect breast cancer	$32M	-	48/100
6th	Curasight 2013, Copenhagen (Denmark), Series A	Developer of PET ligands for breast cancer indications	$11.5M	PreSeed Ventures, PSV Deeptech	47/100
7th	OncoStem 2011, Bengaluru (India), Series A	Developer of prognostic tests for the detection of cancer	$9M	Artiman, Peak XV Partners & 1 others	45/100
8th	Biotheranostics 2008, San Diego (United States), Acquired	Commercial stage molecular diagnostics tests tailored to individual cancer patients.	$32M	MVM, Health Quest Capital & 2 others	44/100
9th	RNA Diagnostics 2010, Toronto (Canada), Series A	Developer of diagnostic assays for the detection of cancer	$13.8M	iGan Partners, BDC & 4 others	41/100
10th	Inbiomotion 2010, Barcelona (Spain), Series A	Developer of biomarkers to predict bone metastasis in cancer patients	$4.91M	Ysios Capital, Caixa Capital Risc & 4 others	40/100
42nd	MeCo Diagnostics 2022, San Diego (United States), Seed	Developer of predictive biomarker tests for breast cancer care	-	Team Ignite Ventures, EvoNexus & 1 others	29/100